Aarti Drugs Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
AARTIDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts more than Nifty Microcap 250 and 0.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aarti Drugs Limited reported standalone total income of ₹15,844 lakh for FY2026, down from ₹18,131 lakh in FY2025 — a ~12.6% revenue decline on a standalone basis. However, consolidated total income grew to ₹2,40,339 lakh from ₹2,19,162 lakh in the prior year, reflecting the contribution from subsidiaries including a large Indian subsidiary (Pinnacle Life Science / Aarti Speciality Chemicals) and foreign subsidiaries (Pharma Go SpA, Tripharma Chile SpA). Standalone PAT grew ~16% to ₹5,174 lakh (PY: ₹4,455 lakh). Consolidated PAT was ₹16,810 lakh (PY: ₹16,816 lakh), marginally flat. The Board declared an un-modified audit opinion, re-appointed GMVP & Associates LLP as Cost Auditor and M/s Raman S. Shah & Co. as Internal Auditor, and reconstituted the Risk Management Committee by adding Shri Narendra J. Salvi as a member.
Standalone revenue contracted sharply while PAT grew on cost controls; consolidated revenue expanded driven by newly consolidated subsidiaries. Clean audit and stable PAT are positive, but the standalone revenue decline warrants monitoring.